Pipeline Overview

Our Development Programs

Program (click indication for details)
Phase 1
Phase 2
Phase 3
NDA / MAA Approved

ADASUVE®: Staccato loxapine

To see full prescribing information, including boxed warning, visit www.ADASUVE.com or the EMA website

AZ-002: Staccato alprazolam

Treatment to rapidly abort seizure activity
For more information, visit AZ-002
Licensed by Engage Therapeutics

AZ-003: Staccato FENTANYL

Cancer breakthrough pain.
For more information, contact This email address is being protected from spambots. You need JavaScript enabled to view it.

AZ-007: Staccato zaleplon

Middle of the night awakening.
For more information, visit AZ-007

To discuss partnership and licensing opportunities,
please contact our Business Development Group.

Early Development

Parkinson’s Disease

Patients often experience unwanted symptoms such as motor fluctuations from chronic medication that can be disruptive in their daily lives. Rapid and acute treatment is highly desirable to minimize off periods, wearing off and freezing.

Corporate Headquarters
2091 Stierlin Court
Mountain View, CA 94043
TEL: 650 944 7000
FAX: 650 944 7999
Email Us
Back to top
Scroll for more